Who is eligible for clinical trial NCT06506422?

Participants must meet protocol criteria for Aging. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT06506422 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-02-04

Empagliflozin Reversal of Arterial StiffnEss in Aging (NCT06506422)

🟢 Recruiting Phase2 / Phase3 💊 Investigational Drug / Biologic Sponsor: University of Missouri-Columbia

🩺 Plain-English Summary (8th-Grade Level)

Randomized placebo-controlled clinical trial in a cohort of males (n=40) and females (n=40), 60-80 years of age, with the hypothesis that SGLT2 inhibition with empagliflozin (10mg/day for 12 weeks) reduces aging-related arterial stiffening.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (4 items) and avoid the listed exclusions (18 items).

Location: University of Missouri — Columbia, Missouri

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Able to provide consent
60 to 80 years of age at randomization (women must be postmenopausal defined as more than 1 year without menses)
Stable anti-hypertensive medication regimen (if in use) for at least 90 days
Evidence of arterial stiffening (defined as carotid-femoral PWV \>/= 8 m/s) at the time of screening visit.

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Diabetes
BMI\>/= 45kg/m2
Known history of cardiovascular disease: heart failure, ischemic heart disease, peripheral artery disease or stroke
Estimated glomerular filtration rate GFR \< 29 mL/min
Active cancer (excluding basal cell carcinoma or stage 1 squamous cell carcinoma of the skin)
Excessive alcohol consumption (\>14 drinks/week for men, \>7 drinks/week for women)
Use of hormone replacement therapy
Body weight change ≥10% within the last 6 months
Uncontrolled hypertension during screening visit (\>180/110 mmHg)
Symptomatic hypotension and/or a SBP \<100 mmHg
History of ketoacidosis

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (1 Sites)

University of Missouri — Columbia, Missouri

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

🏛️ View Official NIH Record ↗